Sulfasalazine-induced immune thrombocytopenia.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 17551063.
- Also identified by PMC identifier 2600053.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sulfasalazine is a well established disease-modifying anti-rheumatic drug commonly used in the treatment of rheumatic disorders and inflammatory bowel disease. Sulfasalazine was generally well tolerated in clinical trials, the most frequently reported adverse effects being adverse gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. We are now reporting the first case of autoimmune thrombocytosis following sulfasalazine treatment.
Medical subject headings
- Antirheumatic Agents
- Arthritis, Psoriatic
- Purpura, Thrombocytopenic, Idiopathic
- Sulfasalazine